Medicalgorithmics has announced the launch of a research collaboration with a leading medical university in Lund, Sweden. The initiative aims to create the world’s largest dataset on cardiac function based on artificial intelligence and to establish a new global standard in non-invasive cardiac diagnostics using the Virtual Cardiac Stress Test (VCAST).
The project will utilize the VCAST platform to analyze data from the SCAPIS study – one of the most comprehensive cardiac imaging projects in the world, involving over 30,000 participants. The collaboration seeks to validate the clinical utility of AI-driven cardiac function assessments developed by Medicalgorithmics at a population level and to support the development of the next generation of non-invasive diagnostic tools.
“Once analyses conducted via VCAST are complete, we will possess the world’s largest population study assessing cardiac function through AI, enabling us to validate and further develop the clinical relevance of this solution,”
said Prof. Gunnar Engström, principal investigator of the SCAPIS project at Lund University.
VCAST (Virtual Cardiac Stress Testing) is a platform developed by Medicalgorithmics (initiated seven years ago by Biofund, the company’s largest shareholder), powered by artificial intelligence. It enables simulation and analysis of cardiac function under stress conditions using non-invasive data. By integrating deep learning with advanced physiological modeling, VCAST supports early detection of cardiovascular risk and may serve as a non-invasive alternative or complement to traditional methods, such as stress echocardiography, SPECT, or cardiac stress MRI.
“This collaboration marks a groundbreaking moment for the future of non-invasive cardiac diagnostics. By combining the world-class scientific expertise of Lund University with our VCAST platform, we aim to set a new global standard in cardiac function assessment. Leveraging the world’s largest cardiac function dataset not only accelerates clinical research but also paves the way for a strategic AI platform that could power the next generation of predictive and personalized cardiology,”
said Dr. Krzysztof Siemionow, MD, PhD, CEO of Medicalgorithmics.
SCAPIS (Swedish CArdioPulmonary bioImage Study) is a national research initiative that integrates advanced imaging, biomarkers, and clinical data, allowing for a comprehensive assessment of cardiovascular and pulmonary risk factors. The collaboration between Medicalgorithmics and Lund University will leverage SCAPIS data to evaluate the clinical relevance of the VCAST platform and its potential to influence future diagnostic standards.
Disclaimer: The information contained in this publication is for informational purposes only. It does not constitute financial or any other type of advice, is general in nature, and is not addressed to any specific individual. Before using this information for any purpose, independent advice should be sought.
Source: managerplus.pl
